Abstract:AIM: To observe the clinical effect of half-dose verteporfin photodynamic therapy(PDT)in the treatment of chronic central serous chorioretinopathy(CSCR).
METHODS: It was a retrospective case series analysis. Nineteen eyes of 14 patients with CSCR diagnosed by best corrected visual acuity(BCVA), direct ophthalmoscope, fundus fluorescein angiography(FFA)and optical coherence tomography(OCT)were enrolled. The course of the disease was ranged 6～12mo, PDT was applied with half-dose verteporfin(3mg/m2). The patients were observed to determine the anatomic and functional outcomes during 6～12mo of the follow-up. Comparisons of pre- and post-treatment BCVA and central foveal thickness(CFT)were performed using a paired t test.
RESULTS: At the last follow-up visit, the mean BCVA was 0.57±0.08, there was statistical difference compared with that before PDT(t=2.110; P<0.01). Seventeen eyes(89.5%)had improved vision, and 2 eyes(10.5%)had stable vision. The mean CFT was reduced from 368.67±32.18μm to 228.44±56.88μm with statistical significance(t=2.110; P<0.01). The results of OCT showed that subretinal fluid completely disappeared in 17 eyes(89.5%), partly absorbed in 2 eyes(10.5%)after treatment. There was no recurrence during the follow-up.
CONCLUSION: Half-dose of verteporfin PDT is effective and safe for the treatment of chronic or recurrent CSCR.
